Upadacitinib and Dupilumab Demonstrate Superior Efficacy in the Treatment of Adolescent Atopic Dermatitis: A Network Meta-Analysis

Upadacitinib and dupilumab demonstrate strong efficacy and symptom improvement in the treatment of moderate to severe AD in adolescents, particularly in reducing the severity of skin lesions and itchiness. Therefore, these medications should be considered as primary treatment options for adolescents with AD. However, further studies with long-term follow-up and larger sample sizes are necessary to thoroughly investigate the safety profiles of these medications in adolescents. This underscores the importance of closely monitoring the side effects of different drugs during clinical treatment to tailor optimal therapeutic strategies based on individual patient needs.